Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | QPCT | Q16769 | 18/20 | 0.49 |
| ▸ | QPCTL | Q9NXS2 | 2/20 | 0.40 |
| ▸ | FGFR1 | P11362 | 1/20 | 0.36 |
| ▸ | CDK4 | P11802 | 1/20 | 0.36 |
| ▸ | CCNA2 | P20248 | 1/20 | 0.36 |
| ▸ | FGFR2 | P21802 | 1/20 | 0.36 |
| ▸ | FGFR4 | P22455 | 1/20 | 0.36 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.36 |
| ▸ | CCND1 | P24385 | 1/20 | 0.36 |
| ▸ | CDK2 | P24941 | 1/20 | 0.36 |
| ▸ | IP6K1 | Q92551 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12456230 | 0.90 | QPCT (0.52) | QPCTQPCTL | |
| SCHEMBL12456233 | 0.90 | QPCT (0.50) | QPCTQPCTLIP6K1 | |
| SCHEMBL12456210 | 0.90 | QPCT (0.61) | QPCTQPCTL | |
| SCHEMBL12456240 | 0.89 | QPCT (0.48) | QPCTQPCTL | |
| SCHEMBL12456219 | 0.89 | QPCT (0.49) | QPCTQPCTL | |
| SCHEMBL12456234 | 0.88 | QPCT (0.64) | QPCTQPCTL | |
| SCHEMBL12456218 | 0.87 | QPCT (0.48) | QPCTQPCTL | |
| SCHEMBL12274695 | 0.85 | QPCT (0.68) | QPCTQPCTLIP6K1 | |
| SCHEMBL12456226 | 0.85 | QPCT (0.49) | QPCTQPCTL | |
| SCHEMBL12456211 | 0.84 | QPCT (0.51) | QPCTQPCTL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8530670-B2 | Inhibitors | PROBIODRUG AG (DE) | 2013-09-10 | — | — | US | disclosed |
| US-20120237475-A1 | Novel Inhibitors | PROBIODRUG AG (DE) | 2012-09-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120237475-A1 | Novel Inhibitors | GLS, NQO2, GLS2 | QPCT 5/4885QPCTL 13/4885FGFR1 698/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.